The blockbuster drug Ozempic & its other GLP-1 receptor agonists counterparts, once prescribed for diabetes, is now prescribed off label for weight loss. These drugs have become so popular that we are in shortage of them in Australia. Currently, there are limited long term studies on the effects of taking this medication, which begs the question, how informed are individuals taking these drugs? In this episode we have a look at what the scientific literature says so far, as well as some of the emotional & psycho-spiritual factors at play with overweight & obesity that taking this drug bypasses.

Support my workbuymeacoffee.com/angelmunro

Book in a sessionwith me https://www.angel-munro.com/services

Watch

Who is Responsiblefor Four Health? Steps to Take to Keep Your Health in Your Hands.

https://www.youtube.com/watch?v=WV-z1finiRM&t=1161s

Weight ManagementBeyond Diets, Calorie Counting, Macro’s & Fitness Trackers

https://www.youtube.com/watch?v=SImMMaGM7LE

References

Cairns, R., &Buckley, N. (2023). Semaglutide exposures reported to the NSW Poisons Information Centre: Effects of social media marketing and supply chain disruptions. Internal Medicine Journal, 53(4), 654–655.https://doi.org/10.1111/imj.16059

Davis, C., Huggins, C. E., Kleve, S., Leung, G. K. W., & Bonham, M.P. (2024). Conceptualizing weight management for night shift workers: A mixed-methods systematic review. Obesity Reviews, 25(2), e13659.https://doi.org/10.1111/obr.13659

Fleury, N., Geldenhuys, S., & Gorman, S. (2016). Sun Exposure and Its Effects on Human Health: Mechanisms through Which Sun Exposure Could Reduce the Risk of Developing Obesity and Cardiometabolic Dysfunction. InternationalJournal of Environmental Research and Public Health, 13(10), 999.https://doi.org/10.3390/ijerph13100999

Hansen, M. S., Wölfel, E. M., Jeromdesella, S., Møller, J.-J. K.,Ejersted, C., Jørgensen, N. R., Eastell, R., Hansen, S. G., & Frost, M. (2024). Once-weekly semaglutide versus placebo in adults with increased fracture risk: A randomised, double-blinded, two-centre, phase 2 trial. eClinicalMedicine, 72, 102624. https://doi.org/10.1016/j.eclinm.2024.102624

Hibberd, T. J., Ramsay, S., Spencer-Merris, P., Dinning, P. G.,Zagorodnyuk, V. P., & Spencer, N. J. (2023). Circadian rhythms in colonic function. Frontiers in Physiology, 14.https://doi.org/10.3389/fphys.2023.1239278

Iacobucci, G. (2025). GLP-1 agonists: 82 deaths linked to adverse reactions, UK data show. BMJ, 388, r390.https://doi.org/10.1136/bmj.r390

Ju, H. Y., Song, S.-E., Shin, S.-K., Jeong, G.-S., Cho, H.-C., Im,S.-S., & Song, D.-K. (2025). Fulvic acid inhibits the differentiation of 3T3-L1 adipocytes by activating the Ca2+/CaMKⅡ/AMPK pathway. Biochemical and Biophysical Research Communications, 743, 151173. https://doi.org/10.1016/j.bbrc.2024.151173

Lopez-Minguez, J., Gómez-Abellán, P., & Garaulet, M. (2019). Timing of Breakfast, Lunch, and Dinner. Effects on Obesity and Metabolic Risk. Nutrients,11(11), 2624. https://doi.org/10.3390/nu11112624

PA-C, J. F., MMSc. (2025, April 14). How does Ozempic work?Understanding GLP-1s for diabetes, weight loss, and beyond. Harvard Health. https://www.health.harvard.edu/staying-healthy/how-does-ozempic-work-understanding-glp-1s-for-diabetes-weight-loss-and-beyond

Porter, J. L., & Varacallo, M. A. (2025). Osteoporosis. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK441901/

Schlomann, B. H., & Parthasarathy, R. (2019). Timescales of gutmicrobiome dynamics. Current Opinion in Microbiology, 50, 56–63. https://doi.org/10.1016/j.mib.2019.09.011

Zecca, L., Casella, L., Albertini, A., Bellei, C., Zucca, F. A.,Engelen, M., Zadlo, A., Szewczyk, G., Zareba, M., & Sarna, T. (2008). Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson’s disease. Journal ofNeurochemistry, 106(4), 1866–1875.https://doi.org/10.1111/j.1471-4159.2008.05541.x